Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBluecross Idaho IV golimumab Coverage Update | Ope…
    Ask Trek AI about this page
    CurrentBluecross IdahoPolicy MP 5.01.670

    Simponi Aria (golimumab) for Intravenous Use

    Customize your policy alerts

    Sign up for Bluecross Idaho Policy MP 5.01.670 alerts

    Get alerted when Policy MP 5.01.670 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-benefit coverage and prior-authorization criteria for intravenous golimumab (Simponi Aria) for specified inflammatory indications; it affects providers administering IV golimumab and members whose benefit plans follow Blue Cross of Idaho policies.

    Policy Summary
    PayerBluecross Idaho
    PolicySimponi Aria (golimumab) for Intravenous Use
    Policy CodePolicy MP 5.01.670
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Last ReviewSep 25, 2025
    Next Review DateSep 25, 2025
    Key ActionObtain prior authorization with documentation of TB screening within 6 months and required prior therapy history before initiating IV golimumab.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1 yearprior-approval duration
    2 mg/kgadult maintenance dose
    80 mg/m2pediatric maintenance dose
    RA, PsA, AS, pJIAIncluded indications

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    J1602
    HCPCS code

    Coverage Criteria for Intravenous Golimumab (Simponi Aria)

    Initial Therapy

    Covered when ALL of the following are met for initial therapy

    Initial therapy general criteria: Individual has had tuberculosis (TB) screening within 6 months of initiating therapy confirming no active tuberculosis (or prior adequate TB screening if switching from another targeted immune modulator with no new risk factors); if latent tuberculosis infection is present, treatment for the infection is started prior to use of golimumab; golimumab is NOT being used in combination with any other biologic DMARD, targeted synthetic DMARD, or other immunomodulator; dosing is initiated in accordance with FDA-approved labeling and/or accepted drug compendia dosing.TB screening within 6 months

    If switching from another targeted immune modulator with no new risk factors, TB screening is not necessary; see Appendices for concomitant therapy lists.

    Indication-specific criteria: Rheumatoid arthritis: individual is ≥18 years with moderately to severely active RA; golimumab used in combination with methotrexate unless contraindicated or intolerant; inadequate response to methotrexate titrated to maximally tolerated dose, or inadequate response/intolerance/contraindication to other conventional therapy (sulfasalazine, leflunomide, hydroxychloroquine).; Ankylosing spondylitis: individual is ≥18 years with active moderate to severe AS and has had inadequate response to, is intolerant of, or has a contraindication to conventional therapy (e.g., NSAIDs or nonbiologic DMARDs such as sulfasalazine); Psoriatic arthritis: individual is ≥2 years with active moderate to severe PsA and has had inadequate response to, is intolerant of, or has a contraindication to conventional therapy (DMARDs such as methotrexate, sulfasalazine, cyclosporine, or leflunomide); Polyarticular juvenile idiopathic arthritis (pJIA): individual is ≥2 years with active moderate to severe pJIA and has had inadequate response to, is intolerant of, or has a contraindication to conventional therapy (DMARDs such as methotrexate, sulfasalazine, cyclosporine, or leflunomide).age requirements per indication

    Each bulleted indication has its own age and prior-therapy requirements as cited.

    Continuation Therapy

    Continuation Therapy — covered when ALL criteria are met

    Continuation criteria: Coverage criteria for initiation of golimumab therapy for the requested indication have previously been met; there is clinically significant and functionally relevant improvement or stabilization in clinical signs and symptoms of the disease; golimumab is NOT being used in combination with any other biologic DMARD, targeted synthetic DMARD, or other immunomodulator.

    Requests may be considered not medically necessary if the individual has active or untreated latent tuberculosis, hepatitis B, or other active serious infections, or a history of recurrent infections.

    Covered Indications (summary)

    Simponi Aria (golimumab) IV may be considered medically necessary for the following when criteria are met:

    Indications: Rheumatoid arthritis; Ankylosing spondylitis; Psoriatic arthritis; Polyarticular juvenile idiopathic arthritis.

    Policy history and codes list these diagnoses as covered when criteria are met (see ICD-10 groups).

    Subcutaneous golimumab (the SC formulation) is not covered under this medical-benefit policy and is handled through the pharmacy benefit. Coverage, utilization management, and any prior authorization requirements for the SC product are governed by the member’s pharmacy benefit plan and associated formulary rules; therefore subcutaneous golimumab is outside the scope of this medical policy.

    If an individual develops a serious infection or sepsis while receiving a TNF inhibitor (including golimumab), the TNF inhibitor should be discontinued. This action is consistent with the agents’ Black Box Warning and the directive to weigh risks and benefits in patients with serious or recurrent infections.

    Requests for intravenous golimumab may be considered not medically necessary when the documented continuation or initiation criteria are not met, and for all other indications not specified by this policy. Additionally, treatment is not medically necessary for individuals with active or untreated latent tuberculosis, active hepatitis B, other active serious infections, or a history of recurrent infections.

    No additional explicit "not medically necessary" statements beyond those already cited are provided in the referenced portions of the policy; the policy instead details contraindications, safety testing, and circumstances (for example active or untreated latent TB or development of serious infection) under which use would be inappropriate or discontinued.

    Initial Therapy Criteria

    Initial Therapy

    Initial therapy general criteria: Individual has had tuberculosis (TB) screening within 6 months of initiating therapy confirming no active tuberculosis (or prior adequate TB screening if switching from another targeted immune modulator with no new risk factors); if latent tuberculosis infection is present, treatment for the infection is started prior to use of golimumab; golimumab is NOT being used in combination with any other biologic DMARD, targeted synthetic DMARD, or other immunomodulator; dosing is initiated in accordance with FDA-approved labeling and/or accepted drug compendia dosing.TB screening within 6 months

    If switching from another targeted immune modulator with no new risk factors, TB screening is not necessary; see Appendices for concomitant therapy lists.

    Initial therapy safety

    Safety and mechanism considerations for initiating therapy

    Initiation safety checks: Test for latent tuberculosis prior to initiation and treat latent TB before starting golimumab; evaluate risk of serious infection and malignancy (Black Box Warning) and consider the increased risk when used with concomitant immunosuppressants such as methotrexate, azathioprine, or 6-mercaptopurine; discontinue TNF inhibitor if an individual develops a serious infection or sepsis.

    Continuation Criteria

    Continuation

    Continuation: Previous initiation criteria were met for the requested indication; there is clinically significant and functionally relevant improvement or stabilization in clinical signs and symptoms; golimumab is NOT being used in combination with any other biologic DMARD, targeted synthetic DMARD, or other immunomodulator.

    Requests may be considered not medically necessary if the individual has active or untreated latent tuberculosis, hepatitis B, or other active serious infections, or a history of recurrent infections.

    Provider Actions and Documentation Requirements

    Prior Authorization

    Prior authorization required; 1‑year initial approval and FDA/compendia dosing

    Prior authorization is required for intravenous golimumab (Simponi Aria). Initial approvals are limited to a duration of 1 year and dosing must be initiated in accordance with FDA‑approved labeling or accepted drug compendia.

    • Prior‑approval duration: 1 year (see Prior‑Approval Limits)
    • Dosing per FDA labeling or accepted compendia (adult and pediatric loading/maintenance dosing specified)
    Prior Authorization

    Medical-policy review required for IV golimumab; bill with specified codes

    Intravenous golimumab (Simponi Aria) requires medical policy review for medical necessity when requested for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or polyarticular juvenile idiopathic arthritis; infusion billing should use the HCPCS, CPT and NDC codes listed in the policy.

    • HCPCS J1602 (Injection, golimumab, 1 mg, IV) and NDC 57894-0350-01 apply for Simponi Aria

    Billing and Coding

    Coding (see Codes table)mixed
    No codes listed
    HCPCSHCPCS
    J1602Injection, golimumab, 1 mg , for intravenous use only.
    CPT infusion codesCPT
    96365Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug).
    96366Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug).
    96367Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug).
    96368Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug).
    NDCNDC
    57894-0350-01Simponi Aria 50 mg/4mL injection, single-dose vial.
    ICD-10ICD-10
    M05.00-M06.9Rheumatoid Arthritis (RA).
    M08.00-M08.99Juvenile Idiopathic Arthritis (pJIA).
    L40.50-L40.59Psoriatic Arthritis (PsA).
    M45.0-M45.9Ankylosing Spondylitis (AS).
    TB screening window
    TB screening windowTB screening test within 6 months of initiating therapy confirming no active tuberculosis; if latent TB present, treatment started prior to golimumab
    Switching from another targeted immune modulatorPrior adequate TB screening acceptable if no new risk factors when switching therapies
    Documentation requirementRecord of TB test date and result must be provided with prior authorization request
    None specified
    None specifiedNo threshold or numeric value specified in the policy for this item

    Step Therapy and Prior Treatment Requirements

    RequirementDetails
    Prior failure, intolerance, or contraindication required
    Rheumatoid arthritis: inadequate response to methotrexate titrated to maximally tolerated dose, or intolerance/contraindication to methotrexate with inadequate response or intolerance to other conventional therapy (sulfasalazine, leflunomide, hydroxychloroquine)
    Ankylosing spondylitis: inadequate response to, intolerance of, or contraindication to conventional therapy (eg, NSAIDs or nonbiologic DMARDs such as sulfasalazine)
    Psoriatic arthritis: inadequate response to, intolerance of, or contraindication to conventional therapy (DMARDs such as methotrexate, sulfasalazine, cyclosporine, or leflunomide)
    Polyarticular juvenile idiopathic arthritis: inadequate response to, intolerance of, or contraindication to conventional therapy (DMARDs such as methotrexate, sulfasalazine, cyclosporine, or leflunomide); age ≥2 years
    Policy referenceWhat to consider
    Appendix 1 — Conventional DMARDs list
    Consider prior use, intolerance, or contraindication to conventional DMARDs listed in Appendix 1 (eg, methotrexate, sulfasalazine, leflunomide, hydroxychloroquine, azathioprine, cyclosporine)
    Appendix 1 — Biological DMARDs list
    Policy also references biological DMARDs in Appendix 1 (eg, abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab) and targeted/other agents when assessing prior or concurrent therapy

    Quantity Limits and Dosing

    Simponi Aria (golimumab) 50 mg/4 mL vial
    Vial strengthSimponi Aria (golimumab) 50 mg/4 mL single-dose vial (available dosage form)
    Dosing basisDosing per weight or body surface area per FDA labeling/accepted compendia: adults 2 mg/kg maintenance every 8 weeks; pediatrics 80 mg/m2 maintenance every 8 weeks
    Prior-approval limitsInitial authorization limited to 1 year; loading doses and maintenance dosing specified in prior-approval limits

    Site of Care / Benefit Application

    Billing Rule

    Infusion center: administer under the medical benefit in appropriate clinical infusion setting

    Infusion of intravenous golimumab is covered under the medical benefit and must be administered in an appropriate clinical infusion setting in accordance with medical‑benefit rules.

    • IV golimumab is a medical‑benefit drug (subcutaneous formulation is pharmacy benefit and outside this medical policy)
    Billing Rule

    Outpatient/home infusion: permitted places of service and billing guidance

    Infusions may be administered in outpatient physician office, infusion clinic, or home health settings per place‑of‑service guidance; bill using the applicable outpatient medical place of service codes.

    • Place of service guidance lists outpatient settings: physician office, infusion clinic, or home health

    Definitions

    TNF inhibitor (TNFi)
    DefinitionTumor necrosis factor inhibitor (TNFi): a class of biologic agents that neutralize tumor necrosis factor alpha, reducing inflammation
    Clinical noteGolimumab is classified as a TNFi; TNFi agents have important safety considerations including a Black Box Warning for serious infections and malignancy
    Mechanism contextTNFi reduce TNF-mediated inflammatory activity implicated in RA, PsA, and AS
    Golimumab
    Drug class and identityGolimumab: human monoclonal antibody that binds soluble and transmembrane TNF-alpha
    Pharmacologic actionPrevents TNF-alpha binding to its receptors, inhibiting TNF-mediated biological activity

    Background

    Golimumab is a human monoclonal antibody of the IgG1κ subclass that binds both soluble and transmembrane forms of tumor necrosis factor alpha (TNFα), inhibiting TNF-mediated inflammatory activity. It is used to treat several chronic inflammatory conditions and is classified as a TNF inhibitor (TNFi), a class with a Black Box Warning for serious infections and malignancy; prior authorization is used to ensure appropriate, safe, and cost-effective IV use.

    Policy Summary
    PayerBluecross Idaho
    PolicySimponi Aria (golimumab) for Intravenous Use
    Policy CodePolicy MP 5.01.670
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Last ReviewSep 25, 2025
    Next Review DateSep 25, 2025
    Key ActionObtain prior authorization with documentation of TB screening within 6 months and required prior therapy history before initiating IV golimumab.
    SourceLink
    On This Page
    Coverage Criteria for Intravenous Golimumab (Simponi Aria)Initial Therapy CriteriaContinuation CriteriaProvider Actions and Documentation RequirementsBilling and CodingStep Therapy and Prior Treatment RequirementsQuantity Limits and DosingSite of Care / Benefit ApplicationDefinitionsBackground

    Monitor for infections and malignancy risk; document TB testing prior to and during therapy as indicated.

  1. Use appropriate CPT infusion codes (96365–96368) for infusion administration
  2. Step Therapy

    Requirement: prior inadequate response/intolerance/contraindication to conventional therapies

    For RA, AS, PsA, and pJIA, documentation must show prior inadequate response, intolerance, or contraindication to conventional therapies (for RA, methotrexate titrated to maximally tolerated dose unless contraindicated; for AS/PsA/pJIA, relevant conventional DMARDs/NSAIDs as noted).

    • RA: inadequate response to methotrexate titrated to maximally tolerated dose, or intolerance/contraindication to methotrexate and other conventional therapies (sulfasalazine, leflunomide, hydroxychloroquine)
    • AS: inadequate response/intolerance/contraindication to conventional therapy (e.g., NSAIDs or nonbiologic DMARDs)
    • PsA and pJIA: inadequate response/intolerance/contraindication to conventional DMARDs (e.g., methotrexate, sulfasalazine, cyclosporine, leflunomide)
    Note

    Refer to Appendix 1 DMARD lists when assessing prior therapies

    Policy references Appendix 1 lists of conventional, biologic, and targeted synthetic DMARDs that must be considered when documenting prior treatment history and step‑therapy decisions.

    • Appendix 1 includes conventional DMARDs (e.g., methotrexate, sulfasalazine, leflunomide, hydroxychloroquine) and biologic DMARDs (e.g., abatacept, adalimumab, infliximab, golimumab) for reference
    Documentation Required

    Document TB screening within 6 months prior to initiation

    Document tuberculosis (TB) screening within 6 months prior to initiation showing no active tuberculosis; if switching from another targeted immune modulator with no new risk factors, prior TB screening may suffice.

    • If latent TB is present, documentation must show treatment was started prior to golimumab use
    • If switching from another targeted agent that required TB screening at initiation and there are no new risk factors, repeat TB screening is not necessary
    Documentation Required

    Document latent TB testing before initiation and during therapy; record indication and infusion data

    Document testing for latent tuberculosis before initiation and during therapy, and include the requested indication and relevant baseline/administration data (diagnosis and infusion details such as HCPCS/CPT/NDC).

    • Record indication (e.g., RA, PsA, AS, pJIA) and infusion coding: HCPCS J1602, CPT 96365–96368, NDC 57894-0350-01
    • Document baseline TB test results and any TB treatment started prior to initiation
    Denial Risk

    Denial risk: active/untreated latent TB, hepatitis B, or other active serious infections

    Requests may be considered not medically necessary if the individual has active or untreated latent tuberculosis, active hepatitis B, other active serious infections, or a history of recurrent infections.

    • Policy states IV golimumab is NOT medically necessary when these infection risks are present
    • Repeat TB testing not required for ongoing therapy, but active/untreated infections preclude approval
    Denial Risk

    Denial risk/discontinuation if serious infection or lack of required TB testing

    Use of TNF inhibitors should be discontinued and may be denied or discontinued if the individual develops a serious infection or sepsis; failure to test for latent TB prior to initiation could influence coverage decisions.

    • TNFi (including golimumab) should be discontinued if a serious infection or sepsis develops
    • Testing for latent TB before and during therapy is required; lack of testing/treatment for latent TB may affect medical‑necessity determinations
    Coding context
    This placeholder aligns with coding/threshold entries where no specific limit applies
    Use guidanceIf a future threshold is added, it will be documented in the Coding or Thresholds section of the policy
  3. Use HCPCS/CPT/NDC codes as documented in the policy for billing (J1602, 96365–96368, NDC 57894-0350-01)
  4. Biologic effectsModulates expression of adhesion proteins (E-selectin, ICAM-1, VCAM-1) and secretion of proinflammatory cytokines (IL-6, IL-8, G-CSF, GM-CSF)
    TNF inhibitor black box safety
    Black Box safety summaryTNF inhibitors including golimumab have a Black Box Warning for serious infections and malignancy
    TB testing requirementIndividuals should be tested for latent tuberculosis before TNFi use and during therapy; treat latent TB prior to initiation
    Action on serious infectionDiscontinue TNFi if an individual develops a serious infection or sepsis
    Additional risksReported malignancies in children/adolescents; cases of hepatosplenic T-cell lymphoma observed with concomitant azathioprine or 6-mercaptopurine